Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Pfizer Inc. announced that it initiated a phase III, lead-in study of an experimental gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B. Fidanacogene elaparvovec, a high-activity human coagulation factor IX gene, is a one-time treatment option.